ArticleInvestigative ophthalmology & visual science2013
Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.
Article in Investigative ophthalmology & visual science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 60 citations in OpenAlex.
- A fatty acid amide activates myeloid cells and improves neurovascular outcomes in retinal degeneration.Nature neuroscience · 2026Article
- Porous Silicon Nanoparticle Hydrogel Formulation for Topical Delivery of Flightless I Neutralizing Antibody and Improved Diabetic Wound Healing.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Exosomes-based dual drug-loaded nanocarrier for targeted and multiple proliferative vitreoretinopathy therapy.Regenerative biomaterials · 2024Article
- Intravitreal safety profiles of sol-gel mesoporous silica microparticles and the degradation product (Si(OH)Drug delivery · 2020Article
- A sustained dual drug delivery system for proliferative vitreoretinopathy.Drug delivery · 2020Article
- Single subconjunctival injection formulation using sol-gel mesoporous silica as a controlled release system for drop-free post-cataract surgery care.Journal of cataract and refractive surgery · 2020Article
- Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy.Drug delivery · 2018Article
- Mesoporous Silicon Particles Favor the Induction of Long-Lived Humoral Responses in Mice to a Peptide-Based Vaccine.Materials (Basel, Switzerland) · 2018Article
- Presumed Chemotherapy-Induced Optic Neuropathy and Maculopathy: A Case Report.The open ophthalmology journal · 2017Article
- A sustained intravitreal drug delivery system with remote real time monitoring capability.Acta biomaterialia · 2015Article
- A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics.Investigative ophthalmology & visual science · 2015Article
- Surface engineering of porous silicon microparticles for intravitreal sustained delivery of rapamycin.Investigative ophthalmology & visual science · 2015Article
- Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2015Article
- Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide.Experimental eye research · 2014Article
- Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin.Acta biomaterialia · 2014Article
- Oxidation-Induced Trapping of Drugs in Porous Silicon Microparticles.Chemistry of materials : a publication of the American Chemical Society · 2014Article
- Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.Journal of controlled release : official journal of the Controlled Release Society · 2014Article
- Cefazolin-loaded mesoporous silicon microparticles show sustained bactericidal effect against Staphylococcus aureus.Journal of tissue engineering · 2014Article
- pH-responsive drug delivery system based on hollow silicon dioxide micropillars coated with polyelectrolyte multilayers.Nanoscale research letters · 2014Article
- Sustained delivery of a HIF-1 antagonist for ocular neovascularization.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo test the feasibility of covalent loading of daunorubicin into oxidized porous silicon (OPS) and to evaluate the ocular properties of sustained delivery of daunorubicin in this system.
methodsPorous silicon was heat oxidized and chemically functionalized so that the functional linker on the surface was covalently bonded with daunorubicin. The drug loading rate was determined by thermogravimetric analysis. Release of daunorubicin was confirmed in PBS and excised rabbit vitreous by mass spectrometry. Daunorubicin-loaded OPS particles (3 mg) were intravitreally injected into six rabbits, and ocular properties were evaluated through ophthalmic examinations and histology during a 3-month study. The same OPS was loaded with daunorubicin using physical adsorption and was evaluated similarly as a control for the covalent loading.
resultsIn the case of covalent loading, 67 ± 10 μg daunorubicin was loaded into each milligram of the particles while 27 ± 10 μg/mg particles were loaded by physical adsorption. Rapid release of daunorubicin was observed in both PBS and excised vitreous (~75% and ~18%) from the physical adsorption loading, while less than 1% was released from the covalently loaded particles. Following intravitreal injection, the covalently loaded particles demonstrated a sustained degradation of OPS with drug release for 3 months without evidence of toxicity; physical adsorption loading revealed a complete release within 2 weeks and localized retinal toxicity due to high daunorubicin concentration.
conclusionsOPS with covalently loaded daunorubicin demonstrated sustained intravitreal drug release without ocular toxicity, which may be useful to inhibit unwanted intraocular proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.